

## Das nephrotische Syndrom im Erwachsenenalter

### Syndrome néphrotique de l'adulte

#### Literatur / Références

- Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. *BMJ* 2008;336:1185–9
- Llach F. Thromboembolic complications in the nephrotic syndrome. Coagulation abnormalities, renal vein thrombosis and other conditions. *Postgrad Med* 1984;76:1111–4,116–8,121–3
- Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. *Am J Kidney Dis* 1997;30:621–31
- Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. *Am J Kidney Dis* 1996;27:647–51
- Orth SR, Ritz E. The nephrotic syndrome. *N Engl J Med* 1998;338:1202–11
- Rivera F, López-Gómez JM, Pérez-García R. Clinicopathologic correlations of renal pathology in Spain. *Kidney Int* 2004;66:898–904
- Geers AB, Koomans HA, Roos JC, Boer P, Dorhout Mees EJ. Functional relationships in the nephrotic syndrome. *Kidney Int* 1984;26:324–30
- Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL et al. Role of intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. *J Clin Invest* 1983;71:91–103
- Férraille E, Vogt B, Rousset M, Barlet-Bas C, Cheval L, Doucet A et al. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. *J Clin Invest* 1993;91:1295–300
- Perico N, Remuzzi G. Edema of the nephrotic syndrome: the role of the atrial peptide system. *Am J Kidney Dis* 1993;22:355–66
- Svenningsen P, Bistrup C, Friis UG, Bertozzi M, Haerteis B, Krueger B et al. Plasmin in nephrotic urine activates the epithelial sodium channel. *J Am Soc Nephrol* 2009;20:299–310
- Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. *Kidney Int* 1998;53:1111–7
- Ruggenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. *BMJ* 1998;316:504–9
- de Seigneux S, Martin PY. Management of patients with nephrotic syndrome. *Swiss Med Wkly* 2009;139:416–22
- Rabelink TJ, Zwavinga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. *Kidney Int* 1994;46:287–96
- Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. *Circulation* 2008;117:224–30
- Li YJ, Xie C, Xia ZM. Risk factors for infection in adult nephrotic syndrome. *Chinese J Nephrol* 1996;12:76–8
- Ogi M, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. *Am J Kidney Dis* 1994;24:427–36
- Koomans HA. Pathophysiology of acute renal failure in idiopathic nephrotic syndrome. *Nephrol Dial Transplant* 2001;16:221–4
- Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. *J Am Soc Nephrol* 2006;17 (4 Suppl 2):S145–7
- Charlesworth JA, Gracey DM, Pussell BA. Adult nephrotic syndrome: non-specific strategies for treatment. *Nephrology* 2008;13:45–50
- KDIGO Clinical practice guidelines for glomerulonephritis. *Kidney Int Supplements* 2012;2,156–62
- Brater DC. Diuretic therapy. *N Engl J Med*. 1998;399:387–95
- Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. *Ann Intern Med* 2011;154:541–48
- Weiner DE, Tighiouart H, Levey AS, Elsayed E, Griffith JL, Salem DN et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. *J Am Soc Nephrol* 2007;18:960–6
- Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *J Clin Invest* 2006;116:288–96
- Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. *Am J Kidney Dis* 2008;52:475–85

28. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA et al. Telmisartan to prevent recurrent stroke and cardiovascular events. *N Engl J Med* 2008;359:1225–37
29. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med* 2012;367:2204–13
30. Shavit L, Lifschitz MD, Epstein M. Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. *Kidney Int* 2012;81:955–68
31. Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. *Kidney Int* 2004;65:1991–2002
32. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. *J Am Soc Nephrol* 2007;18:2221–5
33. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M et al. Venous thromboembolism in patients with membranous nephropathy. *Clin J Am Soc Nephrol* 2012;7:43–51